Is Draft Guidance More Than Meets The Eye? Senators Seek Answers From FDA
This article was originally published in The Gray Sheet
Executive Summary
Republicans on the Senate HELP Committee say they are concerned that FDA is using draft guidance documents to set substantive policy, which they argue puts companies in a difficult position.
You may also be interested in...
'Major' Pain For FDA: Under OMB Directive, Congress Will Vote On So-Called 'Major' Rules, Guidance Docs
New regulations and guidance documents from the US FDA will soon have to undergo scrutiny from the Office of Management and Budget to determine whether they're "major" and should therefore be reviewed and approved by Congress. The direction from OMB acting Director Russell Vought in an April 11 memo will undoubtedly delight some in the medical device industry who have complained for years that the FDA uses voluntary guidance documents to actively drive regulatory decisions.
CDRH Can’t Rely On ‘Network of Experts’ Due To Confidentiality Concerns
CDRH Director Jeff Shuren told a Senate panel April 28 that an obstacle to getting outside expertise on innovative devices to gain the know-how to appropriately review them is companies’ confidentiality concerns, and inability of firms to share access to their proprietary data.
CDRH Can’t Rely On ‘Network of Experts’ Due To Confidentiality Concerns
CDRH Director Jeff Shuren told a Senate panel April 28 that an obstacle to getting outside expertise on innovative devices to gain the know-how to appropriately review them is companies’ confidentiality concerns, and inability of firms to share access to their proprietary data.